LuciMito 500 mg Tablet

Description

LuciMito Mitotane, an essential treatment option for patients facing inoperable adrenal cortical carcinoma, whether functional or nonfunctional. This powerful cytotoxic drug is designed to effectively target and manage this challenging condition. With a recommended initial dosage of 2 g to 6 g taken orally in three or four divided doses daily, LuciMito Mitotane allows for gradual dose adjustments to achieve optimal blood concentrations between 14 to 20 mg/L, tailored to each patient's tolerance. Take control of your treatment journey with LuciMito Mitotane. To maintain their therapeutic integrity, tablets should be swallowed whole—never chewed or crushed. Please adhere to special handling and disposal procedures to ensure safety. LuciMito Mitotane for a focused approach towards managing adrenal cortical carcinoma, empowering you to take the next step in your health journey.